UBS O'Connor’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-106,800
Closed -$33.8M – 627
2023
Q4
$33.8M Buy
+106,800
New +$20.8M 1.06% 11

Other funds holding KRTX

UBS O'Connor's KRTX Position: Q1 2024 in Review

UBS O'Connor sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 106,800 shares — an estimated $33.8M sold.

UBS O'Connor first reported a position in KRTX in Q4 2023 and held it in 1 quarter. The position peaked at $33.8M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • UBS O'Connor reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • UBS O'Connor sold 106,800 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $33.8M.
  • UBS O'Connor first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • UBS O'Connor's Karuna Therapeutics, Inc. Common Stock position peaked at $33.8M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on UBS O'Connor's 13F filing for Q1 2024, filed 15 May 2024.